Summary of GE HealthCare Technologies FY Conference Call Company Overview - **Company**: GE HealthCare Technologies (NasdaqGS:GEHC) - **Date of Conference**: March 10, 2026 Key Industry Insights - **Middle East Exposure**: - GE HealthCare's exposure to the Middle East is less than 5% of its overall business, indicating limited risk from regional disruptions [5][7] - The company is focused on ensuring safety and continuity of operations amidst regional conflicts [3][4] - **Oil Price Impact**: - The company is monitoring the implications of rising oil prices but has multiple levers to offset potential impacts, including pricing strategies and productivity initiatives [12][13] - Logistics costs are more affected by oil prices than the cost of goods sold, as the company does not have a significant resin component in its products [15] - **Tariff Management**: - Tariff expenses were approximately $250 million last year and are expected to decrease this year [18] - The company successfully mitigated initial tariff impacts from $1 billion to $250 million through strategic supply chain management [19] - Recent tariff changes, including the replacement of IEEPA tariffs with Section 122 tariffs, are expected to have similar financial impacts [20][21] Product and Innovation Highlights - **Product Launches**: - GE HealthCare has launched several innovative products, including: - **Vivid Pioneer**: A cardiovascular ultrasound device that reduces echocardiograph time and enhances image quality [34] - **Allia Moveo**: A next-generation X-ray machine for interventional procedures [35] - **LOGIQ R5**: A general ultrasound imaging device that significantly reduces scan time and clicks [36] - **Future Product Expectations**: - Anticipated launches of **total body PET** and **photon-counting CT** are expected to drive significant revenue growth, primarily in 2027 [40][41] - The company has a record backlog of $2 billion year-over-year, supporting its growth forecast of 3%-4% for the current year [32] Competitive Landscape - **Generic Competition**: - Amneal's entry into the market with a generic version of GE HealthCare's iohexol product is acknowledged, but the company remains confident in its market position due to consistency of supply, product quality, and brand recognition [28][29] Financial Outlook - **Growth Projections**: - The company expects a growth rate of 3%-4% driven by commercial initiatives and a strong product pipeline, with a focus on maintaining a resilient supply chain [30][32] - The impact of new product innovations is expected to be more pronounced in 2027, with some contributions anticipated in the latter half of 2026 [41][42] Conclusion - GE HealthCare Technologies is navigating current geopolitical and economic challenges while focusing on innovation and strategic supply chain management to sustain growth and mitigate risks. The company is well-positioned to leverage its product pipeline and market leadership in the medical devices sector.

Summary of GE HealthCare Technologies Conference Call Company Overview - **Company**: GE HealthCare Technologies (NasdaqGS:GEHC) - **Event**: 2026 Conference - **Date**: February 26, 2026 Key Industry Insights - **Market Concerns**: The company entered 2026 with concerns about the impact of the Affordable Care Act (ACA), capital expenditures (CapEx), and weather affecting medical procedures [3][6] - **Focus Areas**: Emphasis on executing in a dynamic environment, driving commercial excellence, enhancing margins, and focusing on innovation [6][7] Financial Performance - **Orders Growth**: Achieved 5% orders growth in 2025, with organic revenue growth of 3.5% [6][7] - **2026 Guidance**: Projecting 3%-4% organic growth for 2026, based on strong commercial performance from 2025 [90][97] - **Revenue Impact**: Significant revenue impact from new product launches expected in 2027, with limited immediate impact in 2026 [9][97] Product Innovations - **Photonov Spectra**: Anticipated FDA approval in 2026, with revenue impact starting in 2027 [9][10] - **Total Body PET/CT**: Launching outside the U.S. with plans to enter the U.S. market, representing a significant opportunity [20][21] - **AVS Business**: Strong performance attributed to innovation, with shorter sales cycles for certain products [13][14] - **New Product Launches**: Recent launches include Vivid Pioneer, Allia Moveo, and LOGIQ R5, aimed at improving efficiency in healthcare procedures [29][30][31] Competitive Landscape - **R&D Investment**: Increased R&D investment over the past five years, aiming for parity or better with competitors [15][41] - **Market Position**: Strong competitive position in imaging, with a focus on customer-backed innovation and partnerships [41][42] Strategic Collaborations - **UCSF Partnership**: Announced a new 10-year collaboration with UCSF to enhance care delivery through innovation [42][44] - **M&A Activity**: Active in M&A, focusing on strategic acquisitions that align with company goals and enhance product offerings [82][84] Challenges and Risks - **Tariff Impacts**: Ongoing concerns regarding tariffs, with potential offsets from new tariffs affecting financial performance [126][130] - **China Market**: Facing challenges in the Chinese market, with local competitors posing significant threats [156][157] Future Outlook - **Innovation Cycle**: Anticipated discussions in the next year will focus on the impact of the innovation cycle and operational excellence through the Heartbeat system [171][172] - **Long-Term Growth**: Expectation of mid-single-digit growth over the midterm, with a focus on sustaining high margins through innovation [110][113] Conclusion - GE HealthCare Technologies is positioned for growth through innovation and strategic partnerships, despite facing challenges in market dynamics and regulatory environments. The focus remains on enhancing product offerings and operational efficiency to drive future success.

Financial Data and Key Metrics Changes - The company reported revenue of $5.7 billion for Q4 2025, growing 4.8% organically year-over-year, exceeding expectations [14] - Full year revenue reached $20.6 billion, with organic growth of 3.5%, ahead of guidance [15] - Adjusted EBIT margin for 2025 was 15.3%, a decline of 100 basis points year-over-year, impacted by approximately $245 million in tariff expenses [16] - Adjusted EPS for 2025 was $4.59, growing 2.2%, with a tariff impact of $0.43 [16] - Free cash flow for Q4 was $916 million, up $105 million year-over-year, and $1.5 billion for the full year [15][22] Business Line Data and Key Metrics Changes - **Imaging**: Organic revenue grew 5.3% in Q4, driven by strong performance in EMEA and the U.S., particularly in nuclear medicine [17] - **Advanced Visualization Solutions**: Organic revenue increased 4.2% in Q4, supported by new product adoption [18] - **Patient Care Solutions**: Organic revenue declined 1.1% year-over-year due to a drop in life support solutions, but EBIT margin improved sequentially [19] - **Pharmaceutical Diagnostics**: Achieved organic sales growth of 12.7%, driven by global growth in contrast media [20] Market Data and Key Metrics Changes - Demand in the U.S. and EMEA remained strong, with a record backlog of $21.8 billion, growing $2 billion year-over-year [14] - The company secured multiple large agreements, including a significant collaboration with Sutter Health and a multi-year agreement with the Ministry of Health in Indonesia [10][11] Company Strategy and Development Direction - The company is focused on an innovation renaissance, emphasizing integrated solutions for complex and chronic diseases [4] - The strategic framework includes precision care, growth acceleration, and business optimization, with a strong emphasis on the Heartbeat business system to improve productivity and customer experience [11][12] - The planned acquisition of Intelerad is expected to enhance the company's cloud-first imaging ecosystem and drive recurring revenue [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver over $500 million in Flyrcado revenue by year-end 2028, viewing it as a billion-dollar opportunity in the long run [10] - The company anticipates organic revenue growth of 3%-4% for 2026, with a cautious outlook on China impacting overall guidance [22][23] - Management highlighted the importance of new product launches and regulatory approvals in driving future growth [30] Other Important Information - The company has made significant investments in innovation, totaling over $1.7 billion in 2025, to strengthen competitiveness and support growth [17] - The company is focused on expanding recurring revenue through service agreements and has seen positive trends in service growth [72] Q&A Session Summary Question: Can you provide more color on the 2% order growth and outlook for orders in 2026? - Management noted a robust book-to-bill ratio of 1.06x and a record backlog, indicating a solid order backdrop despite a challenging first quarter comparison [27][28] Question: What is the current state of Flyrcado and its adoption? - Management reported positive feedback from clinicians regarding Flyrcado's image quality and convenience, with consistent delivery rates improving [31][32] Question: How should we think about the assumptions for China and potential EPS upside? - Management took a cautious approach regarding China, anticipating a decline in 2026 but noting improvements in VBP win rates and a robust imaging funnel [40][41] Question: Can you elaborate on the pricing strategy for 2026? - Management indicated that while there are no significant price increases expected initially, new product launches may lead to better pricing opportunities later in the year [77] Question: What is the status of the Intelerad acquisition? - The acquisition is expected to close in the first half of the year and is anticipated to enhance the company's capabilities in cloud-enabled AI solutions [79][80]

Financial Data and Key Metrics Changes - The company reported revenue of $5.7 billion for Q4 2025, representing a 4.8% organic growth year-over-year, exceeding expectations [14] - For the full year 2025, revenue reached $20.6 billion, with organic growth of 3.5%, ahead of guidance [16] - Adjusted EBIT margin for Q4 was 16.7%, down 200 basis points due to tariff expenses and unfavorable mix [14] - Adjusted EPS for Q4 was $1.44, down 0.7%, but grew 11% when excluding tariff impacts [15] - Free cash flow for Q4 was $916 million, up $105 million year-over-year [15] Business Line Data and Key Metrics Changes - Pharmaceutical Diagnostics saw organic sales growth of 12.7%, driven by global growth in contrast media and pricing execution [20] - Imaging organic revenue grew 5.3% in Q4, with strong performance in EMEA and the US, particularly in nuclear medicine [17] - Advanced Visualization Solutions reported organic revenue growth of 4.2%, supported by new product adoption [18] - Patient Care Solutions experienced a 1.1% decline in organic revenue due to a drop in life support solutions, but EBIT margin improved sequentially [19] Market Data and Key Metrics Changes - Demand in the U.S. and EMEA remained strong, with a record backlog of $21.8 billion, up $2 billion year-over-year [14] - The company secured multiple large agreements, including a significant collaboration with Sutter Health and a multi-year agreement with the Ministry of Health in Indonesia [10][11] Company Strategy and Development Direction - The company is focused on an innovation renaissance, emphasizing integrated solutions for complex and chronic diseases [4] - The strategic framework includes precision care, growth acceleration, and business optimization, with a strong emphasis on the Heartbeat business system to drive productivity and customer experience [11][12] - The planned acquisition of Intelerad is expected to enhance the company's cloud-first imaging ecosystem and drive recurring revenue [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver over $500 million in Flyrcado revenue by year-end 2028, viewing it as a billion-dollar opportunity in the long run [10] - The company anticipates organic revenue growth of 3%-4% for 2026, with a cautious outlook on China impacting overall guidance [22][23] - Management highlighted the importance of new product launches and regulatory approvals in driving future growth [30] Other Important Information - The company has made significant investments in innovation, deploying over $1.7 billion in 2025 to strengthen competitiveness [17] - The service business grew mid-single digits in 2025, with expectations for increased capture rates of service agreements due to new product launches [11] Q&A Session Summary Question: Can you provide more color on the 2% order growth and outlook for orders in 2026? - Management noted a robust order backdrop with a book-to-bill ratio of 1.06 times and a record backlog, indicating a solid setup for 2026 [27][28] Question: What is the current state of Flyrcado and its adoption? - Management reported positive feedback from clinicians regarding Flyrcado's image quality and convenience, with consistent delivery rates improving [31][32] Question: How should we think about the potential upside in EPS related to China? - Management took a cautious approach regarding China, anticipating a decline in 2026 but noting improvements in VBP win rates and a robust imaging funnel [40][41] Question: Can you elaborate on the timing of orders and sales for new products? - Management indicated that significant new product launches are on track, with expected contributions primarily in 2027, but some impact anticipated in 2026 [60][61] Question: What are the expectations for pricing in 2026? - Management indicated that while there are no significant price increases expected initially, new products may lead to higher pricing as they are introduced [77]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenue of $5.7 billion, representing a 4.8% organic growth year-over-year, exceeding expectations [13] - For the full year 2025, total revenue reached $20.6 billion, with organic growth of 3.5%, ahead of guidance [15] - Adjusted EBIT margin for Q4 was 16.7%, down 200 basis points due to tariff expenses and unfavorable mix [13] - Adjusted EPS for Q4 was $1.44, down 0.7%, but grew 11% when excluding tariff impacts [14] - Free cash flow for Q4 was $916 million, up $105 million year-over-year [15] Business Line Data and Key Metrics Changes - Pharmaceutical Diagnostics saw organic sales growth of 12.7%, driven by global growth in contrast media and pricing execution [19] - Imaging organic revenue grew 5.3% in Q4, with strong performance in EMEA and the US, particularly in nuclear medicine [17] - Advanced Visualization Solutions reported a 4.2% organic revenue increase, supported by new product adoption [18] - Patient Care Solutions experienced a 1.1% decline in organic revenue due to a drop in life support solutions, but EBIT margin improved sequentially [19] Market Data and Key Metrics Changes - Demand in the U.S. and EMEA remained strong, with a record backlog of $21.8 billion, up $2 billion year-over-year [13] - The company secured multiple large agreements, including a significant collaboration with the University of Rochester Medical Center [4] - The capital equipment environment in the U.S. is robust, with many customers planning to increase investments in 2026 [3] Company Strategy and Development Direction - The company is focused on an innovation renaissance, emphasizing integrated solutions for complex and chronic diseases [3] - The strategic framework includes precision care, growth acceleration, and business optimization, with a strong emphasis on the Heartbeat business system to drive productivity and customer experience [10][11] - The planned acquisition of Intelerad is expected to enhance the company's cloud-first imaging ecosystem and drive recurring revenue [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering over $500 million in Flyrcado revenue by year-end 2028, with a long-term billion-dollar opportunity [9] - The outlook for 2026 includes organic revenue growth of 3%-4%, with a cautious approach to the Chinese market [22] - Management anticipates a decline in China for 2026 but sees potential upside if conditions improve [41] Other Important Information - The company deployed over $1.7 billion in innovation investment in 2025, prioritizing programs that strengthen competitiveness [17] - The service business grew mid-single digits in 2025, with expectations for increased capture rates of service agreements due to new product launches [10] Q&A Session Summary Question: Can you provide more color on the 2% order growth and outlook for orders in 2026? - Management noted a robust order backdrop with a book-to-bill ratio of 1.06 times and a record backlog, indicating a positive setup for 2026 [27][28] Question: What is the current state of Flyrcado and its adoption? - Management reported positive feedback from clinicians regarding Flyrcado's image quality and convenience, with consistent delivery rates improving [31][32] Question: How does the company view the situation in China and its impact on EPS? - Management took a cautious approach regarding China, anticipating a decline in 2026 but monitoring for potential upside as conditions evolve [40][41] Question: Can you elaborate on the assumptions for 2026 EPS guidance? - Management explained that the guidance reflects expected volume growth and cost initiatives, with a focus on maintaining investments in growth [44][48] Question: What is the status of the Intelerad acquisition? - The acquisition is expected to close in the first half of the year, enhancing the company's capabilities in cloud-enabled AI solutions [79][80]

Core Insights - Artificial intelligence (AI), particularly generative AI, is rapidly transforming the MedTech industry, enhancing product development, manufacturing, sales personalization, and patient care [1] - The FDA is supportive of innovative medical devices incorporating AI, with 209 AI-enabled devices approved by 2025 [2] - AI is becoming a central efficiency driver in MedTech, improving operations, supply chains, and commercial functions while reducing costs and enhancing quality control [3] Company Highlights - Companies like Stryker (SYK), Tempus AI (TEM), and GE HealthCare Technologies (GEHC) are positioned favorably for investors due to their strong AI integration and growth prospects [4] - Stryker's Mako SmartRobotics platform enhances surgical precision and generates recurring revenue through implants and services, with a projected earnings growth rate of 11.2% for 2025 [11][13] - Tempus AI is expanding its AI algorithms across various medical fields and has secured FDA clearances for its cardiac imaging platform, with a projected earnings growth rate of 58.9% for 2025 [14][16] - GE HealthCare is collaborating with NVIDIA to improve medical imaging and diagnostics, with a projected sales growth rate of 4.3% for 2025 [17][20] AI Applications in Medical Specialties - Interventional pulmonology is well-suited for AI integration, improving procedure planning and management of pulmonary diseases [5] - AI technologies enhance diagnostic procedures by creating virtual maps of the lung and analyzing pathological specimens, leading to improved accuracy [6] - Radiology has seen significant AI investment, with 956 AI-enabled devices approved, enhancing diagnostic precision and clinical workflows [7] - AI applications in oncology are transforming cancer management through data analytics, medical imaging, and clinical decision support [8]

Core Insights - GE HealthCare has raised its fiscal year 2025 profit outlook to between $3.02 and $3.04 per share due to solid demand across all business segments in Q3 2025 [1] - The company achieved revenues of $5.9 billion in Q3, reflecting a 6% increase compared to Q3 2024, and now expects profits of $4.51 to $4.63 per share, up from previous estimates [1] Revenue Breakdown - Patient Care Solutions and Pharmaceutical Diagnostics revenues rose by 6% and 20% in Q3 to $731 million and $749 million, respectively [2] - Imaging and Advanced Visualization Solutions contributed significantly, with revenues increasing by 5% and 7% to approximately $2.34 billion and $1.3 billion, respectively [2] Strategic Initiatives - CEO Peter Arduini emphasized the competitive advantage of the company's "synergistic portfolio" of diagnostic imaging equipment, radiopharmaceuticals, AI, cloud, and software [3] - Strong commercial execution in Q3 is expected to drive nearly $500 million in future revenue, enhancing growth momentum [3] Partnerships and Acquisitions - GE HealthCare established a 14-year care alliance with UC San Diego Health to focus on early detection and cancer care advancements [4] - The acquisition of AI-based brain imaging company icometrix aims to enhance MR imaging capabilities for neurological disorders [4] Technology Integration - The integration of icometrix technologies into MR systems is expected to strengthen the company's portfolio for Alzheimer's care [5] - The incorporation of CaptionAI into the Vscan Air SL wireless handheld ultrasound system has improved margins for new products [5] Recent Product Launches - In the past six months, GE HealthCare has released software that combines imaging functionalities with MIM Software tools to enhance workflows in oncology and cardiology [6] - The launch of Vivid Pioneer, a new cardiovascular ultrasound system that integrates AI, aims to improve imaging speed and quality [6]

Core Insights - The company is leveraging its broad portfolio and service capabilities to deepen customer relationships and create predictable revenue streams through strategic investments and acquisitions [1][4][19] - There is robust growth in contrast media and nuclear medicine, with a strong commercial execution leading to significant revenue from large system deals [2][5] - The company reported a 4% organic revenue growth in the third quarter, driven by strong demand across all segments and a healthy capital equipment environment [3][5][6] Financial Performance - Revenues reached $5.1 billion, reflecting a 4% year-over-year organic growth, with service revenue growing 6% and product revenue up 5% [5][6] - Adjusted EBIT margin was 14.8%, down 150 basis points year over year, primarily due to tariff impacts, but excluding this, the margin would have expanded [6][7][8] - Free cash flow for the quarter was $483 million, with a conversion rate of 99% [15][19] Segment Performance - Imaging segment organic revenue grew 4%, with strong demand in EMEA and the US, although EBIT margin declined due to tariff pressures [10][11] - Advanced Visualization Solutions (AVS) saw a 6% organic revenue increase, with a 180 basis point EBIT margin improvement driven by volume growth [12][13] - Pharmaceutical Diagnostics delivered a strong quarter with 10% organic revenue growth, although EBIT margins declined due to planned investments [14][15] Strategic Initiatives - The integration of icometrix technologies into MR systems aims to enhance the Alzheimer's care pathway, showcasing the company's D3 strategy [4][19] - The company is focused on operational improvements and reducing tariff impacts, having mitigated approximately 50% of its gross tariff exposure for 2025 [4][10] - A disciplined capital allocation strategy is in place, with a focus on organic growth and evaluating M&A opportunities [17][19] Innovation and R&D - Over $3 billion has been invested in R&D since 2022 to deliver differentiated products, with AI-powered systems launched across various segments [19][20] - New product launches, including AI-enabled solutions, are expected to drive faster growth and higher margins [20][22] - The company anticipates significant growth from its new products and innovations, particularly in the imaging and patient care solutions segments [22][23]

Financial Performance - Organic revenue grew 4% year-over-year, with total revenues of $5.1 billion [9][10] - Adjusted EPS was $1.07, down 6% year-over-year, impacted by approximately $0.16 from tariffs [10][18] - Free cash flow was $483 million, down $168 million year-over-year, primarily due to higher receivables and tariff payments [17] Business Segment Performance - Imaging segment organic revenue increased by 4%, with EBIT margin declining by 260 basis points due to tariff pressures [12] - Advanced Visualization Solutions (AVS) saw organic revenue growth of 6% and EBIT margin increased by 180 basis points [13] - Patient Care Solutions (PCS) experienced a 7% decline in organic revenue due to a product hold, with EBIT margin down 680 basis points [15] - Pharmaceutical Diagnostics (PDx) reported a strong quarter with 10% organic revenue growth, although EBIT margin declined by 150 basis points due to planned investments [16] Market Performance - Strong growth observed in EMEA and the U.S. markets, with robust orders growth of 6% across all segments [4][9] - The company is optimistic about the recovery in the Chinese market, with improvements in tender activity [28][29] Company Strategy and Industry Competition - The company is focused on executing its precision care strategy and has invested over $3 billion in R&D since 2022 [20] - A 14-year care alliance with UC San Diego Health was announced, emphasizing the company's commitment to innovative solutions in cancer care [5] - The planned acquisition of icometrix aims to enhance capabilities in Alzheimer's care, showcasing the company's strategy to integrate digital tools into its offerings [7] Management Commentary on Operating Environment and Future Outlook - Management raised adjusted EPS guidance for the full year, reflecting strong performance and healthy capital investment trends [18] - The company expects to deliver free cash flow of at least $1.4 billion for the full year, despite tariff impacts [18] - Management remains confident in achieving mid-single-digit organic growth in the medium term, supported by ongoing innovation and product launches [31][32] Other Important Information - The company has mitigated approximately 50% of its 2025 gross tariff exposure and aims for a lower net tariff impact in 2026 [8] - The company is preparing to introduce a significant number of new AI-powered products at the upcoming RSNA conference [24] Q&A Session Summary Question: Update on growth in China - Management noted improvements in tender activity and expressed optimism about the long-term potential of the Chinese market [28][29] Question: Revenue growth acceleration and targets - Management confirmed confidence in achieving mid-single-digit organic growth, with expectations that China’s stability will support this goal [30][31] Question: Performance in Q3 and guidance for Q4 - Management reiterated full-year revenue guidance, expecting 3%-4% growth in Q4, with a recovery in PCS contributing to this [37] Question: Flyrcado product ramp-up - Management indicated a slower ramp in 2025 due to prioritizing customer experience, with expectations for significant growth in 2026 and beyond [40][42] Question: Photon counting technology update - Management confirmed plans are on track for photon counting technology, with more details expected at the upcoming RSNA [48][49] Question: Patient Care Solutions performance - Management acknowledged the decline in PCS due to a product hold but expressed confidence in recovery and future growth under new leadership [50][51] Question: Opportunities in electrophysiology - Management highlighted the potential in electrophysiology, particularly in the ASC setting, and emphasized their competitive positioning [56][57]

Financial Performance - Organic revenue grew 4% year over year, with total revenues of $5.1 billion [9][10] - Adjusted EPS was $1.07, down 6% year over year, impacted by approximately $0.16 from tariffs [10][19] - Free cash flow was $483 million, down $168 million year over year, primarily due to higher receivables and tariff payments [18] Business Segment Performance - Imaging segment organic revenue increased by 4%, with a decline in EBIT margin of 260 basis points due to tariff pressures [13] - Advanced Visualization Solutions (AVS) saw organic revenue growth of 6% and EBIT margin increased by 180 basis points [14] - Patient Care Solutions experienced a 7% decline in organic revenue due to a product hold, with EBIT margin down 680 basis points [15][16] - Pharmaceutical Diagnostics reported a strong quarter with 10% organic revenue growth, although EBIT margin declined by 150 basis points due to planned investments [17] Market Performance - Strong performance noted in EMEA and the U.S. markets, with robust orders growth of 6% across all segments [4][9] - The company is optimistic about the recovery in the Chinese market, with improvements in tender activity [29][30] Company Strategy and Industry Competition - The company is focused on executing its precision care strategy and has invested over $3 billion in R&D since 2022 [21][24] - Strategic acquisitions, such as icometrix, are aimed at enhancing product offerings and market position [7] - The company is entering a new wave of innovation, particularly in AI-powered products and solutions [24] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit organic revenue growth in the medium term, despite challenges [32][34] - The company raised its adjusted EPS guidance for the full year, reflecting strong performance and healthy capital investment trends [19][20] - Management remains focused on operational improvements and mitigating tariff impacts, with a goal of reducing net tariff impact in 2026 [8][12] Other Important Information - The company has a solid backlog of $21.2 billion, indicating strong future revenue potential [9] - Adjusted EBIT margin was 14.8%, down 150 basis points year over year, primarily due to tariff impacts [10][11] Q&A Session Summary Question: Update on growth in China - Management noted improvements in tender activity and expressed optimism about the long-term potential of the Chinese market [29][30] Question: Confirmation of revenue growth targets - Management confirmed confidence in achieving mid-single-digit organic growth, with expectations for 2026 to exceed current growth rates [32][34] Question: Performance of Patient Care Solutions - Management acknowledged the decline due to a product hold but expects recovery in the fourth quarter [50][51] Question: Opportunities in Electrophysiology - Management highlighted the potential for growth in the ASC setting and the company's leadership position in the market [55][57] Question: Transition of R&D to COGS - Management explained the ongoing transition and its impact on gross margins, with expectations for margin expansion in the fourth quarter [59][60]